What are the recent trends in market size and growth for the minimal residual disease market?
The minimal residual disease market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing number of cancer patients, growing research and development spending, rising healthcare affordability, rising prevalence of blood cancer, and increasing awareness among people.
The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.22 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to rise in the number of patients with cancer, rise in the government awareness programs, rise in the healthcare affordability, increasing disposable income in emerging economies, and government body initiatives to create awareness about cancer. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, adoption of personalized MRD monitoring, development in liquid biopsy technologies, minimal residual disease-directed therapies.
Get Your Free Sample of The Global Minimal Residual Disease Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21224&type=smp
How have varous drivers impacted the growth of the minimal residual disease market?
The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to factors such as an aging population, increased exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. The rising cancer prevalence increases the demand for precise MRD testing to detect residual cancer cells, enabling early intervention and personalized treatment. This improves relapse prediction and enhances patient outcomes. For instance, in May 2024, according to the National Cancer Institute (NCI), a US-based government agency, in 2022 nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally, with projections for 2040 estimating 29.9 million new cases and 15.3 million cancer-related deaths. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease market.
What are the primary segments of the minimal residual disease market?
The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions
Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/minimal-residual-disease-global-market-report
Which firms are leading the minimal residual disease market?
Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.
How will industry trends affect the trajectory of the minimal residual disease market?
Major companies operating in the minimal residual disease (MRD) market are focusing on developing advanced in vitro diagnostic (IVD) test services to provide personalized therapy options for better patient outcomes. An in vitro diagnostic (IVD) test service is a lab-based diagnostic method to detect residual cancer cells after treatment, helping predict relapse and optimize therapy. For instance, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, launched clonoSEQ Assay to detect minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL). This test analyzes circulating tumor DNA (ctDNA) in blood samples to provide a highly sensitive, non-invasive way to monitor cancer progression and detect early signs of relapse. This assay offers clinicians a more precise understanding of a patient’s disease burden, helping them tailor treatment plans accordingly. It is the first minimal residual disease (MRD) test for diffuse large B-cell lymphoma (DLBCL) to receive Medicare coverage, making it widely accessible across all treatment regimens and time points.
Which geographic trends are shaping the minimal residual disease market, and which region has the highest market share?
North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Minimal Residual Disease Market Report 2025 Offer?
The minimal residual disease market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21224
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
